Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chondractiv Move is a dietary supplement formulation developed by Givaudan (formerly Naturex) specifically designed to address activity-related joint discomfort and support cartilage health. The product is a combination of rosehip extract and Chondractiv, a proprietary hydrolyzed chicken cartilage ingredient. Chondractiv provides a natural matrix of type II collagen, chondroitin sulfate, and hyaluronic acid, which are essential structural components of joint tissue. The supplement aims to maintain the balance between cartilage synthesis and degradation, particularly in healthy individuals experiencing functional joint stress or knee pain (gonalgia) following physical activity. By combining the structural support of collagen derivatives with the anti-inflammatory properties of rosehip, Chondractiv Move is intended to improve mobility and flexibility while reducing recovery time after exercise.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chondractiv Move.